ライフサイエンスコーパス: ceftriaxone

1 lation (120 assigned to gatifloxacin, 119 to ceftriaxone).

2 SBL phenotype (based on nonsusceptibility to ceftriaxone).

3 chloramphinicol, amoxicillin-clavulanate and ceftriaxone.

4 were reversed by the beta-lactam antibiotic ceftriaxone.

5 by over 99% outperforming the drug of choice ceftriaxone.

6 r bactericidal effect on S. epidermidis than ceftriaxone.

7 ceftriaxone, and Haemophilus influenzae and ceftriaxone.

8 influenzae in combination with cefotaxime or ceftriaxone.

9 ter one day of treatment with the antibiotic ceftriaxone.

10 fully subcultured by day 3 after exposure to ceftriaxone.

11 the antibiotics imipenem, penicillin G, and ceftriaxone.

12 cortex (mPFC) were quantified in response to ceftriaxone.

13 d decreased susceptibility to penicillin and ceftriaxone.

14 ndomly assigned 358 to gentamicin and 362 to ceftriaxone.

15 y during, and for 72 h after, treatment with ceftriaxone.

16 of DAP-R and elevated MICs to bacitracin and ceftriaxone.

17 gs: cefixime, chloramphenicol, ofloxacin, or ceftriaxone.

18 lin-resistant isolate, increased the MICs of ceftriaxone (0.4 mug/mL) and cefixime (1.2 mug/mL) to le

19 Ceftriaxone 100 mg/kg per injection twice per day (200 m

20 amil 600 mg given every 12 h was superior to ceftriaxone 2 g given every 24 h for the treatment of As

21 s ceftaroline fosamil (600 mg every 12 h) or ceftriaxone (2 g every 24 h) for 5-7 days.

22 articipants were randomly allocated (2:1) to ceftriaxone (2 g or 4 g per day) or placebo.

23 Treatment with ceftriaxone (200 mg/kg, i.p.) upregulated core GLT1 expr

24 Ceftriaxone (200 mg/kg, IP) was administered (vs. saline

25 was 93%, cefpodoxime 84%, cefixime 31%, and ceftriaxone 28%.

26 nol for 48 h during which time they received ceftriaxone (50 or 100 mg/kg, IP) or saline twice a day

27 ther gentamicin 240 mg (gentamicin group) or ceftriaxone 500 mg (ceftriaxone group).

28 240 mg was non-inferior to a single dose of ceftriaxone 500 mg for the treatment of gonorrhoea, when

29 oral solithromycin 1000 mg or intramuscular ceftriaxone 500 mg plus oral azithromycin 1000 mg.

30 tifloxacin (10 mg/kg per day) or intravenous ceftriaxone (60 mg/kg up to 2 g per day for patients age

31 ncomycin (1103, 14.4%; 95% CI, 13.7%-15.2%), ceftriaxone (825, 10.8%; 95% CI, 10.1%-11.5%), piperacil

32 Isolate susceptibility was 100% to ceftriaxone, 95% to penicillin, and 99.9% to ciprofloxac

33 ts provided evidence that the combination of ceftriaxone (a cephalosporin antibiotic) and lansoprazol

34 ses of broad-spectrum antimicrobial therapy (ceftriaxone [a 3rd-generation cephalosporin], ciprofloxa

35 del of ethanol withdrawal, we tested whether ceftriaxone, a beta-lactam antibiotic known to increase

36 lace preference (CPP), we determined whether ceftriaxone, a beta-lactam antibiotic known to increase

37 ne self-administration, while treatment with ceftriaxone, a beta-lactam antibiotic previously shown t

38 NTS (iNTS) was 77.2%, with 15% resistant to ceftriaxone, a drug that is last-line treatment for iNTS

39 Other studies report that ceftriaxone, a glutamate transporter subtype-1 activator

40 nt of CDI in hospitalized patients receiving ceftriaxone, a high-risk antibiotic for CDI.

41 are the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) com

42 y; those with the highest rate had increased ceftriaxone administration and culturable Aspergillus, a

43 orin and azithromycin and those treated with ceftriaxone alone (9.1%; RR, 0.81; 95% CI, .18-3.60) or

44 main of WT PBP2 in complex with cefixime and ceftriaxone, along with structures of PBP2 in the apo fo

45 liary side-effects, participants assigned to ceftriaxone also received 300 mg ursodeoxycholic acid tw

46 Ceftriaxone also reversed the cocaine-induced synaptic p

47 ipenem, filamentous cells with cefoxitin and ceftriaxone), amikacin and phages did not modify cell sh

48 crobials (ampicillin/penicillin, gentamicin, ceftriaxone) among children <=5 years increased from 3.4

49 Ceftriaxone, an antibiotic compound known to increase EA

50 340 participants were randomly allocated to ceftriaxone and 173 to placebo.

51 it 90% of isolates increased by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the

52 r 306 (85%) of 362 participants allocated to ceftriaxone and 292 (82%) of 358 participants allocated

53 Of those patients, 74 (60%) received ceftriaxone and 50 (40%) received oxacillin.

54 ct roles for xCT and GLT-1 in the actions of ceftriaxone and add to a body of literature finding evid

55 rboring blaNDM-1, linked to high exposure to ceftriaxone and amikacin.

56 to defervescence in 17 patients treated with ceftriaxone and azithromycin combination was 3.2 days (+

57 (CDC) currently recommends dual therapy with ceftriaxone and azithromycin for gonorrhea to ensure eff

58 at day 14; among the 190 isolates with lower ceftriaxone and azithromycin MICs, only 13 (7%) had pers

59 Persistence was associated with elevated ceftriaxone and azithromycin MICs.

60 ntly more likely to exhibit elevated MICs of ceftriaxone and azithromycin than isolates from MSW (P <

61 as the undefined mechanisms of resistance to ceftriaxone and azithromycin underscore the importance o

62 ssed include whether to change the dosage of ceftriaxone and azithromycin used in the recommended dua

63 All were susceptible to ceftriaxone and azithromycin.

64 taphylococcus aureus strains were exposed to ceftriaxone and cefazolin at concentrations from 0 to 10

65 mutants to extended spectrum cephalosporins (ceftriaxone and cefepime) identified either PbpF or PonA

66 ephalosporins and the geometric mean MICs of ceftriaxone and cefixime (P < .05 for both comparisons).

67 ance to the expanded-spectrum cephalosporins ceftriaxone and cefixime in Neisseria gonorrhoeae.

68 penA alleles on decreased susceptibility to ceftriaxone and cefixime, with the expectation that this

69 sceptible to failing cephalosporins, such as Ceftriaxone and Cefotaxime.

70 g resistance to tetracycline, norfloxacylin, ceftriaxone and ciprofloxacin were observed among Gram n

71 nt recommend dual therapy with intramuscular ceftriaxone and either azithromycin or doxycycline.

72 We tested penicillin, cefixime, and ceftriaxone and found good agreement between the results

73 the EHR, we found that patients taking both ceftriaxone and lansoprazole had significantly longer QT

74 Combination therapy of ceftriaxone and lansoprazole is associated with increase

75 agnosis, surgical admission, and duration of ceftriaxone and other antibiotics, for each day of doxyc

76 at mutations both lower affinity of PBP2 for ceftriaxone and restrict conformational changes that nor

77 and reduced susceptibility to penicillin and ceftriaxone and still predominated among declining serot

78 eriod at week 14, after the 2-week course of ceftriaxone and the 12-week course of the randomized stu

79 kpoints (2 each for aztreonam, cefepime, and ceftriaxone, and 1 for cefazolin and ceftazidime).

80 ross species, particularly to penicillin and ceftriaxone, and across geographical regions.

81 norrhoeae were susceptible to ciprofloxacin, ceftriaxone, and azithromycin and comprised isolates fro

82 ad negative skin test results to cefuroxime, ceftriaxone, and aztreonam and tolerated challenges.

83 activity between penicillins and cefuroxime, ceftriaxone, and aztreonam in all subjects with T cell-m

84 e subjects could be treated with cefuroxime, ceftriaxone, and aztreonam.

85 ephalexin, cefaclor, cefadroxil, cefuroxime, ceftriaxone, and aztreonam.

86 ibitory concentrations (MICs) of penicillin, ceftriaxone, and cefixime for a wild-type strain (FA19)

87 a species having increased MICs to cefixime, ceftriaxone, and cefpodoxime (mean MIC ratios of 6.27, 4

88 ntrations (MICs) to ciprofloxacin, cefixime, ceftriaxone, and cefpodoxime.

89 r-Kelly medium in the presence or absence of ceftriaxone, and cultures were monitored for up to 56 da

90 , and gentamicin, Neisseria meningitidis and ceftriaxone, and Haemophilus influenzae and ceftriaxone.

91 of various antibiotics (i.e., ciprofloxacin, ceftriaxone, and tetracycline) against Escherichia coli

92 8 patients received prophylactic intravenous ceftriaxone (antibiotic group) and 147 patients did not

93 1:1 to oral (ciprofloxacin) or intravenous (ceftriaxone) antibiotics for 28 days.

94 We find that cefuroxime and ceftriaxone are associated with increased bla(CTX-M) abu

95 Long-term treatment with ceftriaxone attenuates the reinstatement of cocaine seek

96 expression in the NAc.SIGNIFICANCE STATEMENT Ceftriaxone attenuates the reinstatement of cocaine, alc

97 Combination Ceftriaxone-Azithromycin therapy may provide a therapeut

98 ed by the requirement to utilize combination ceftriaxone/azithromycin therapy as the comparator regim

99 fidaxomicin, streptomycin) or gram-negative (ceftriaxone) bacteria on postoperative days (POD) 1-4.

100 ast 12 months (96%), and were treated with a ceftriaxone-based regimen (95%).

101 alosporin and azithromycin was comparable to ceftriaxone-based regimens in the treatment of pharyngea

102 Ceftriaxone blocked methamphetamine-triggered reinstatem

103 ehicle, whereas 100 or 200, but not 50 mg/kg ceftriaxone blocked this response.

104 ll) inputs or treatment with the antibiotic, ceftriaxone, blocked reinstatement of morphine-evoked co

105 ctiveness of gentamicin as an alternative to ceftriaxone (both combined with azithromycin) for treatm

106 n was specific to lansoprazole combined with ceftriaxone but not with other cephalosporins.

107 es (sensitivity 98% for cefixime and 91% for ceftriaxone), but alternative resistance mechanisms have

108 of ciprofloxacin (A), azithromycin (B), and ceftriaxone (C).

109 Ceftriaxone can be dosed once daily and is less expensiv

110 mate transporter GLT-1 (N-acetylcysteine and ceftriaxone) can decrease measures of drug seeking.

111 lutamate in pregabalin-seeking behavior with ceftriaxone (CEF), a potent GLT-1 upregulator.

112 underwent challenges with cefuroxime axetil, ceftriaxone, cefazolin, and ceftibuten; and group C and

113 B was studied in combination with cefazolin, ceftriaxone, cefepime, imipenem, gentamicin, tigecycline

114 Auranofin, in combination with azithromycin, ceftriaxone, cefixime or tetracycline showed an additive

115 determine antimicrobial susceptibilities of ceftriaxone, cefixime, and cefpodoxime in Neisseria gono

116 mine the susceptibility of N. gonorrhoeae to ceftriaxone, cefixime, and cefpodoxime, although we reco

117 agreements were 99.1%, 98.3%, and 94.8% for ceftriaxone, cefixime, and cefpodoxime, respectively.

118 % within 1 log2 dilution from each other for ceftriaxone, cefixime, and cefpodoxime, respectively.

119 lation coefficients of 92%, 91%, and 92% for ceftriaxone, cefixime, and cefpodoxime, respectively.

120 iables (from 2009 to 2015) and 1-year-lagged ceftriaxone, cefixime, azithromycin, and ciprofloxacin g

121 of 264 isolates were subjected to cefazolin, ceftriaxone, cefotaxime, ceftazidime, cefepime, and aztr

122 which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MRSA in

123 , 57 to 87%) sensitive for the prediction of ceftriaxone, ceftazidime, and aztreonam resistance and 7

124 group A, positive responses to 1 or more of ceftriaxone, cefuroxime, cefotaxime, cefepime, cefodizim

125 alone (9.1%; RR, 0.81; 95% CI, .18-3.60) or ceftriaxone combined with azithromycin or doxycycline (1

126 Ceftriaxone combined with metronidazole is superior to c

127 Azithromycin (AZI) is recommended with ceftriaxone (CRO) for treatment of uncomplicated gonococ

128 causative pathogens of CRE infections using ceftriaxone (CRO), ertapenem (ETP), and meropenem (MEM)

129 psy patient with the SLC1A2-modulating agent ceftriaxone did not result in a significant change in da

130 However, ceftriaxone did not reverse stress-induced synaptic pote

131 d immunoprecipitation of GLT-1 revealed that ceftriaxone does not upregulate GLT-1 and xCT through a

132 In this cohort of patients receiving ceftriaxone, doxycycline was associated with lower risk

133 tes had low MICs to amoxicillin, cefotaxime, ceftriaxone, doxycycline, linezolid, meropenem, penicill

134 ice treated with the beta-lactam antibiotic, ceftriaxone, during cocaine withdrawal.

135 Salmonella group B resistant to ceftriaxone emerged in 2009 and 2010 (6.2% [2/32 isolate

136 In separate groups of rats, 200 mg/kg ceftriaxone failed to block cue-induced food seeking, ar

137 istration were treated with the same dose of ceftriaxone followed by intracore or intrashell infusion

138 study groups received open-label intravenous ceftriaxone for 2 weeks before initiating the randomized

139 n in patients being treated with intravenous ceftriaxone for a lower respiratory tract infection, the

140 e aimed to assess the safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis in a combi

141 130 and who were expected to be treated with ceftriaxone for at least 5 days.

142 to be noninferior to the comparator agents (ceftriaxone for CABP and vancomycin plus aztreonam for A

143 In patients treated with intravenous ceftriaxone for lower respiratory tract infections, oral

144 treatment with gentamicin to treatment with ceftriaxone for patients with gonorrhoea.

145 red to identify and test new alternatives to ceftriaxone for the treatment of gonorrhoea.

146 Intra-NAc GLT-1 knockdown also prevented ceftriaxone from attenuating reinstatement and from upre

147 Intra-NAc xCT knockdown prevented ceftriaxone from attenuating reinstatement and from upre

148 were isolated on selective media containing ceftriaxone from the wetland compared to feces, suggesti

149 16% to 27%, and there was a decrease in both ceftriaxone (from 39% to 33%) and azithromycin (change f

150 p were numerically higher than those for the ceftriaxone group (for the clinically evaluable populati

151 a genital infection, 151 (98%) of 154 in the ceftriaxone group and 163 (94%) of 174 in the gentamicin

152 iaxone group had clearance (134 [98%] in the ceftriaxone group compared with 107 [90%] in the gentami

153 red for 299 (98%) of 306 participants in the ceftriaxone group compared with 267 (91%) of 292 partici

154 had clearance at follow-up (108 [96%] in the ceftriaxone group compared with 82 [80%] in the gentamic

155 of participants with rectal infection in the ceftriaxone group had clearance (134 [98%] in the ceftri

156 liary adverse events were more common in the ceftriaxone group than in the placebo group (gastrointes

157 l group and 178 (74%) of 240 patients in the ceftriaxone group were clinically cured at the test-of-c

158 in the gentamicin group vs 21 of 100 in the ceftriaxone group).

159 mg (gentamicin group) or ceftriaxone 500 mg (ceftriaxone group).

160 al infection, a greater proportion receiving ceftriaxone had clearance at follow-up (108 [96%] in the

161 Significantly more participants who received ceftriaxone had serious hepatobiliary serious adverse ev

162 The resistance to ceftriaxone has remained low, suggesting it is likely to

163 tended-spectrum cephalosporins--cefixime and ceftriaxone--have been recommended in the UK for treatme

164 failure, compared with 19 (16%) who received ceftriaxone (hazard ratio [HR] 1.04 [95% CI 0.55-1.98];

165 ns with high-level resistance to cefixime or ceftriaxone heralds the possible demise of beta-lactam a

166 , compared with four (7%) of 54 who received ceftriaxone (HR 0.24 [95% CI 0.08-0.73]; p=0.01).

167 treatment versus 15 (23%) of 65 who received ceftriaxone (HR 7.50 [95% CI 1.71-32.80]; p=0.01).

168 6, cefaclor in 82, and cefuroxime axetil and ceftriaxone in 22 subjects) were well tolerated.

169 e oxyanion hole for acylation and also traps ceftriaxone in a noncanonical configuration.

170 Our data support the role of ceftriaxone in alleviating alcohol withdrawal and open a

171 ising stage 2 data, stage 3 of this trial of ceftriaxone in amyotrophic lateral sclerosis did not sho

172 amil should be regarded as an alternative to ceftriaxone in empirical treatment regimens for this pat

173 Auranofin was found superior to ceftriaxone in reducing the secretion of the pro-inflamm

174 stage 3 (efficacy), participants assigned to ceftriaxone in stage 2 received 4 g ceftriaxone, partici

175 that is required to contact the R1 group of ceftriaxone in the active site.

176 safety of ceftaroline fosamil compared with ceftriaxone in the treatment of Asian patients admitted

177 xacin would be superior to the cephalosporin ceftriaxone in treating enteric fever.

178 these genes that each increase resistance to ceftriaxone, including one mutation that arose independe

179 In addition, ceftriaxone increased glutamate uptake, a primary functi

180 ays disease onset and prolongs survival, and ceftriaxone increases EAAT2 activity.

181 Immunoblotting confirmed that the ceftriaxone-induced blockade of cocaine relapse was asso

182 cue-induced food seeking, arguing against a ceftriaxone-induced effect unique to extinction training

183 small interference RNA completely inhibited ceftriaxone-induced glutamate uptake activity in PHFA.

184 argeting antibiotics, such as vancomycin and ceftriaxone, inhibit the kinase activity of Stk1 and lea

185 after each extinction session, rats received ceftriaxone (intraperitoneally), a beta-lactam antibioti

186 e genetic basis of reduced susceptibility to ceftriaxone is not completely understood: while most cef

187 ptional mechanism, and their coregulation by ceftriaxone is not mediated by physical interaction.

188 Ceftriaxone is recommended when parenteral antibiotic th

189 us pneumoniae with reduced susceptibility to ceftriaxone is reported increasingly, and alternatives a

190 mon sexually transmitted infection for which ceftriaxone is the current first-line treatment, but ant

191 Ceftriaxone is the foundation of currently recommended g

192 0.008 to 2 mug/ml); all were susceptible to ceftriaxone (median MIC, 0.015 mug/ml; range, 0.008 to 1

193 Our results reveal that the ceftriaxone-mediated attenuation of cue-induced cocaine

194 n NAc core, but not shell, would reverse the ceftriaxone-mediated effect.

195 Furthermore, ceftriaxone-mediated upregulation of surface GLT1 expres

196 oxicillin/clavulanic acid MIC >= 256 mug/mL; ceftriaxone MIC >= 8 mug/L).

197 from 1,386 clinical isolates suggest that a ceftriaxone MIC cutoff of 8 mug/ml is an excellent predi

198 oline was generally 16-fold more active than ceftriaxone (MIC(50), 4 mug/mL; MIC(90), 4 mug/mL; 97.9%

199 microg/mL) and was 16-fold more active than ceftriaxone (MIC(90), 2 microg/mL).

200 spectively) and was 16-fold more active than ceftriaxone (MIC(90), 2 microg/mL).

201 ncentrations (MICs) >256 mug/mL and elevated ceftriaxone MICs (>/=0.125 mug/mL).

202 ad azithromycin MICs >16 microg/mL and 5 had ceftriaxone MICs = 0.125 microg/mL by agar dilution.

203 er of clinical microbiology laboratories use ceftriaxone MICs as a proxy means of identifying bacteri

204 Isolates with ceftriaxone minimum inhibitory concentration >/= 1 micro

205 geal and rectal isolates, there were 10 with ceftriaxone minimum inhibitory concentration (MIC) >/=0.

206 Isolates with ceftriaxone minimum inhibitory concentrations >/=2 micro

207 In conclusion, Ceftriaxone modulated the expression of the glutamate tr

208 After treatment with ceftriaxone mono- or dual therapy (with azithromycin or

209 (+/- 1.7), whereas in 13 cases treated with ceftriaxone monotherapy, the time to defervescence was 6

210 preferred choice for definitive treatment of ceftriaxone non-susceptible E. coli and Klebsiella.

211 These data indicate that ceftriaxone normalizes multiple aspects of glutamate hom

212 at at high concentration neither Inh2-B1 nor Ceftriaxone or Cefotaxime alone was able to inhibit the

213 e evaluated MacConkey agar supplemented with ceftriaxone or cefotaxime as a screening method for accu

214 as observed at a micromolar concentration of Ceftriaxone or Cefotaxime in the presence of Inh2-B1.

215 n countries, was prepared with 2 or 4 mug/ml ceftriaxone or cefotaxime.

216 Participants received 2 g ceftriaxone or placebo twice daily through a central ven

217 icipants were randomly assigned (2:1) to 4 g ceftriaxone or placebo.

218 P in combination with AMP, ERT, ceftaroline, ceftriaxone, or amoxicillin against DAP-R E. faecium R49

219 For a ceftazidime, ceftriaxone, or cefotaxime MIC of > or =2 microg/ml, a d

220 strain 536 and received 536_P1 intranasally, ceftriaxone, or control.

221 r patients who are allergic or intolerant to ceftriaxone, or harbour a ceftriaxone-resistant isolate.

222 illin (P<0.0001), ampicillin (P = 0.01), and ceftriaxone (P = 0.006).

223 ity (9 of 50 [18%] oxacillin vs 3 of 74 [4%] ceftriaxone; P = .01).

224 igned to ceftriaxone in stage 2 received 4 g ceftriaxone, participants assigned to placebo in stage 2

225 ug use occurred during the 2-week open-label ceftriaxone phase, and no serious drug-related adverse e

226 000 mg dose is not a suitable alternative to ceftriaxone plus azithromycin as first-line treatment fo

227 romycin, a fourth generation macrolide, with ceftriaxone plus azithromycin for the treatment of gonor

228 s higher in the solithromycin group than the ceftriaxone plus azithromycin group (69 [53%] of 130 pat

229 n group and 109 (84%) of 129 patients in the ceftriaxone plus azithromycin group had N gonorrhoeae er

230 30 in the solithromycin group and 131 in the ceftriaxone plus azithromycin group).

231 rescribing practice in 2010 from cefixime to ceftriaxone plus azithromycin.

232 le-dose systemic therapy (usually injectable ceftriaxone plus oral azithromycin) is the recommended f

233 se and 206 patients were assigned to receive ceftriaxone plus placebo.

234 f whom 207 patients were assigned to receive ceftriaxone plus ribaxamase and 206 patients were assign

235 43 patients developed CDI within 30 days of ceftriaxone receipt, an incidence of 5.60 cases per 10 0

236 Furthermore, ceftriaxone reduced ethanol drinking, suggesting that EN

237 Rapidly emerging resistance against ceftriaxone requires urgent reevaluation of antibiotic r

238 Ceftriaxone resistance among S. pneumoniae was 2.1% (10.

239 We show that penA-independent ceftriaxone resistance has evolved multiple times throug

240 one is not completely understood: while most ceftriaxone resistance in clinical isolates is caused by

241 Ceftriaxone resistance increased in blood isolates from

242 esistance and DCS; rates of azithromycin and ceftriaxone resistance were 0.6% and absent, respectivel

243 lineages are a single nucleotide change from ceftriaxone resistance.

244 pyema; the emergence of multidrug, including ceftriaxone, resistant serotype 19A strains; and the nee

245 c or intolerant to ceftriaxone, or harbour a ceftriaxone-resistant isolate.

246 Among 70 ceftriaxone-resistant pneumococcal isolates, all were in

247 at included identification of culture-proven ceftriaxone-resistant S. Typhi cases, suspected cases fr

248 A total of 101 confirmed cases of ceftriaxone-resistant S. Typhi had been reported in 4 mo

249 biology laboratory identified an outbreak of ceftriaxone-resistant Salmonella Typhi in Hyderabad, Pak

250 From 2012, we have observed an emergence of ceftriaxone-resistant strains also showing reduced susce

251 We also found that ceftriaxone restores glutamate reuptake and attenuates t

252 nd microdialysis to test the hypothesis that ceftriaxone restores the function of both GLT-1 and xCT

253 n that chronic treatment with the antibiotic ceftriaxone restores xCT and GLT-1 expression following

254 e acid signaling and lipid metabolism, while ceftriaxone resulted in greater reduction of key antimic

255 ecreased susceptibility to both cefixime and ceftriaxone rose between 2007 and 2010 but was more noti

256 In particular, ceftriaxone significantly decreases the growth rate of a

257 LOLA (as an add-on therapy to lactulose and ceftriaxone) significantly improves the grade of OHE ove

258 n, Streptococcus pneumoniae, vancomycin, and ceftriaxone, Streptococcus agalactiae, ampicillin, and c

259 y related gonococcal isolates with decreased ceftriaxone susceptibility and high-level azithromycin r

260 several of which also demonstrated decreased ceftriaxone susceptibility.

261 more slowly in participants who received 4 g ceftriaxone than in those on placebo (difference 0.51 un

262 utamate transport in the accumbens core with ceftriaxone the capacity of acute stress to augment the

263 Except for the last trial with ceftriaxone, the fluoroquinolone gatifloxacin was associ

264 creasing Neisseria gonorrhoeae resistance to ceftriaxone, the last antibiotic recommended for empiric

265 In cultures treated with ceftriaxone, the pH of the culture medium did not change

266 47 (98%) of 48 isolates were susceptible to ceftriaxone (third-generation cephalosporin), and 57 (93

267 Notably, all organisms were susceptible to ceftriaxone throughout the study period (2005-2014), and

268 changes likely account for the inability of ceftriaxone to attenuate cocaine relapse in cocaine + al

269 CT and GLT-1 are essential to the ability of ceftriaxone to attenuate cue-induced reinstatement of co

270 We also tested the ability of ceftriaxone to attenuate the reinstatement of cocaine-se

271 June 2005 and 31 December 2010 who received ceftriaxone to determine whether the additional receipt

272 ctrophysiology to investigate the ability of ceftriaxone to normalize measures of synaptic plasticity

273 s were followed from first administration of ceftriaxone to occurrence of CDI or administrative closu

274 of both proteins in mediating the ability of ceftriaxone to prevent cue-induced reinstatement of coca

275 By adding antibodies to antibiotic (ceftriaxone)-treated mice, we further reduce the bacteri

276 PCR for up to 56 days in aliquots from both ceftriaxone-treated and untreated cultures.

277 We found that 5 d of ceftriaxone treatment following cocaine self-administrat

278 the ceftaroline treatment group than in the ceftriaxone treatment group (59 of 69 [85.5%] vs 48 of 7

279 Similarly, ceftriaxone treatment prevented stress-induced potentiat

280 In addition, although ceftriaxone treatment resulted in a reduction in the qua

281 Finally, ceftriaxone treatment was associated with lasting upregu

282 nt, noncultivable Borrelia burgdorferi after ceftriaxone treatment was examined.

283 In the absence of cocaine or ceftriaxone treatment, xCT knockdown in the NAc increase

284 We found a significant reduction in ceftriaxone use with a concomitant increase in targeted

285 In this comparison of ceftriaxone versus oxacillin for MSSA osteoarticular inf

286 MSSA osteoarticular infections treated with ceftriaxone versus oxacillin.

287 ession with oral antibiotics (31 of 74 [42%] ceftriaxone vs 25 of 50 [50%] oxacillin; P = .4).

288 illin; P = .7) and >6 months (43 of 56 [77%] ceftriaxone vs 26 of 32 [81%] oxacillin; P = .6).

289 ss was similar at 3-6 months (50 of 60 [83%] ceftriaxone vs 32 of 37 [86%] oxacillin; P = .7) and >6

290 bo group (gastrointestinal, 245 of 340 [72%] ceftriaxone vs 97 of 173 [56%] placebo, p=0.0004; hepato

291 The outcome after 14-day treatment with ceftriaxone was favorable in 87.8% of patients.

292 rapy of intravenous daptomycin, rifampin and ceftriaxone was initiated.

293 Additionally, under our study conditions, ceftriaxone was suboptimum in a high proportion of patie

294 d of care treatment (including lactulose and ceftriaxone) was given in both groups.

295 administration of the beta-lactam antibiotic ceftriaxone, which promotes synaptic glutamate clearance

296 Multidrug resistance, including to ceftriaxone, will pose further difficulty in management

297 A total of 56.0% of patients received ceftriaxone with metronidazole (hospital range: 0%-100%)

298 In the multivariable model, ceftriaxone with metronidazole was associated with a 90%

299 ducibility of broth microdilution testing of ceftriaxone with N. cyriacigeorgica and N. wallacei, tig

300 Ceftriaxone with or without a macrolide antibiotic is a